0001104659-23-057486.txt : 20230509 0001104659-23-057486.hdr.sgml : 20230509 20230509075010 ACCESSION NUMBER: 0001104659-23-057486 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230501 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230509 DATE AS OF CHANGE: 20230509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DarioHealth Corp. CENTRAL INDEX KEY: 0001533998 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 452973162 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-37704 FILM NUMBER: 23900026 BUSINESS ADDRESS: STREET 1: 18 W 18TH ST., 5TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10011 BUSINESS PHONE: 646.665.4667 MAIL ADDRESS: STREET 1: 18 W 18TH ST., 5TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10011 FORMER COMPANY: FORMER CONFORMED NAME: LabStyle Innovations Corp. DATE OF NAME CHANGE: 20111101 8-K/A 1 tm2315045d1_8ka.htm FORM 8-K/A
0001533998 true --12-31 On May 5, 2023, DarioHealth Corp. (the "Company") filed a Current Report on Form 8-K in connection with the closing of a private placement offering and the execution of a loan and security agreement (the "Prior 8-K"). This Current Report on Form 8-K/A (the "8-K/A") is being filed to clarify the reduced number of warrant shares to be issued to the lender as well as clarify the reduced number of shares potentially issuable to holders of the Company's Series A-1 Preferred Stock. No other changes were made to the Prior 8-K and this Form 8-K/A should be read in connection with the Prior 8-K. Accordingly, except as specifically noted above, this Form 8-K/A does not reflect events occurring after the filing of the Prior 8-K. Unless filed herewith, references to the exhibits in this Form 8-K/A are references to the exhibits filed with the Prior 8-K. 0001533998 2023-05-01 2023-05-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K/A

(Amendment No. 1)

 

CURRENT REPORT

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): May 5, 2023 (May 1, 2023)

 

DARIOHEALTH CORP.

(Exact name of registrant as specified in its charter)

 

Delaware  001-37704  45-2973162
(State or other jurisdiction
of incorporation)		  (Commission
File Number)		  (IRS Employer
Identification No.)

 

18 W. 18th St, 5th Floor

New York, New York 10011

(Address of Principal Executive Offices)

 

972- 4-770-4055

(Issuer’s telephone number)

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class   Trading
Symbol(s)		   Name of exchange on which 
registered
Common Stock, par value $0.0001 per share   DRIO   The Nasdaq Capital Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Explanatory Note

 

On May 5, 2023, DarioHealth Corp. (the “Company”) filed a Current Report on Form 8-K in connection with the closing of a private placement offering and the execution of a loan and security agreement (the “Prior 8-K”). This Current Report on Form 8-K/A (the “8-K/A”) is being filed to clarify the reduced number of warrant shares to be issued to the lender as well as clarify the reduced number of shares potentially issuable to holders of the Company’s Series A-1 Preferred Stock.

 

No other changes were made to the Prior 8-K and this Form 8-K/A should be read in connection with the Prior 8-K. Accordingly, except as specifically noted above, this Form 8-K/A does not reflect events occurring after the filing of the Prior 8-K. Unless filed herewith, references to the exhibits in this Form 8-K/A are references to the exhibits filed with the Prior 8-K. 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

Series B Preferred Stock Securities Purchase Agreement

 

On May 1, 2023, DarioHealth Corp. (the “Company”) entered into securities purchase agreements (each, a “Series B Purchase Agreement”) with accredited investors relating to an offering (the “Offering”) and the sale of an aggregate of 6,200 shares of newly designated Series B Preferred Stock (the “Series B Preferred Stock”), an aggregate of 7,946 shares of Series B-1 Preferred Stock (the “Series B-1 Preferred Stock”), and an aggregate of 150 shares of Series B-2 Preferred Stock (the “Series B-2 Preferred Stock”) at a purchase price of $1,000 for each share of Preferred Stock. Certain of our executive officers and directors purchased shares of Series B-2 Preferred Stock in the Offering. On May 5, 2023, the Company entered into purchase agreements (the “Series B-3 Purchase Agreement” and together with the Series B Purchase Agreement, the “Purchase Agreement”) with accredited investors, relating to the Offering, to an offering and the sale of an aggregate of 1,106 shares of newly designated Series B-3 Preferred Stock (the “Series B-3 Preferred Stock” and, collectively with the Series B Preferred Stock, the Series B-1 Preferred Stock and the Series B-2 Preferred Stock, the “Preferred Stock”), at a purchase price of $1,000 for each share of Preferred Stock. As a result of the sale of the Preferred Stock, the aggregate gross proceeds to the Company from the Offering are approximately $15.4 million. The closing of the Series B Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock occurred on May 4, 2023, and the closing of the Series B-3 Preferred Stock is expected to occur on or before May 9, 2023.

 

On May 1, 2023, the Company filed the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, the Certificate of Designation of Preferences, Rights and Limitations of the Series B-1 Preferred Stock, and the Certificate of Designation of Preferences, Rights and Limitations of the Series B-2 Preferred Stock with the Secretary of State of the State of Delaware (the “Series B Certificate of Designation,” the “Series B-1 Certificate of Designation,” and the “Series B-2 Certificate of Designation”). On May 5, 2023, the Company filed the Certificate of Designation of Preferences, Rights and Limitations of the Series B-3 Preferred Stock (the “Series B-3 Certificate of Designation,” and together with the “Series B Certificate of Designation,” the “Series B-1 Certificate of Designation,” and the “Series B-2 Certificate of Designation, collectively, the “Certificates of Designation”). Each share of Preferred Stock is convertible at the option of the holder, subject to certain beneficial ownership limitations as set forth in each of the Certificates of Designation, into such number of shares of Company’s common stock (the “Common Stock”) equal to the number of Preferred Shares to be converted, multiplied by the stated value of $1,000 (the “Stated Value”), divided by the conversion price in effect at the time of the conversion (the initial conversion price of the Series B Preferred Stock and Series B-1 Preferred Stock is $3.334, the initial conversion price of the Series B-2 Preferred Stock is $3.37, and the initial conversion price of the Series B-3 Preferred Stock is $3.392) each subject to adjustment in the event of stock splits, stock dividends, and similar transactions.

 

In addition, the Preferred Stock will automatically convert into shares of Common Stock, subject to certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker, on the 15-month anniversary of the issuance date. The holders of Preferred Stock will also be entitled dividends payable as follows: (i) a number of shares of Common Stock equal to five percent (5.0%) of the number of shares of Common Stock issuable upon conversion of the Preferred Stock then held by such holder for each full quarter anniversary of holding for a total of four (4) quarters from the Closing Date, and (ii) a number of shares of Common Stock equal to ten percent (10%) of the number of shares of Common Stock issuable upon conversion of the Preferred Stock then held by such holder on the fifth full quarter from the Closing Date.

 

The Series B Preferred Stock and Series B-3 Preferred Stock will vote together with the Common Stock as a single class on an as-converted basis on any matter presented to the shareholders of the Company. The Series B-1 Preferred Stock and Series B-2 Preferred Stock do not possess any voting rights with respect to such matters. Upon any liquidation, dissolution or winding-up of the Company, after the satisfaction in full of the debts of the Company and payment of the liquidation preference to the Senior Securities, holders of Preferred Stock shall be entitled to be paid, on a pari passu basis with the payment of any liquidation preference afforded to holders of any Parity Securities, the remaining assets of the Company available for distribution to its stockholders. For these purposes, (i) “Parity Securities” means the Common Stock, Series B Preferred Stock, Series B-1 Preferred Stock, the Series B-2 Preferred Stock, the Series B-3 Preferred Stock and any other class or series of capital stock of the Company hereinafter created that expressly ranks pari passu with the Series B Preferred Stock, Series B-1 Preferred Stock, the Series B-2 Preferred Stock and/or the Series B-3 Preferred Stock; and (ii) “Senior Securities” shall mean any class or series of capital stock of the Company hereafter created which expressly ranks senior to the Parity Securities.

 

 

The Purchase Agreement also provides for certain registration rights pursuant to which the Company agreed to file a registration statement covering the resale of the shares of Common Stock issuable upon conversion of the Preferred Stock within sixty days following the date of the Purchase Agreement.

 

The Purchase Agreements contain representations and warranties that the parties made to the others in the context of all of the terms and conditions of that agreement and in the context of the specific relationship between the parties. The provisions of such agreements, including the representations and warranties contained therein, are not for the benefit of any party other than the parties to such agreement and are not intended as documents for investors and the public to obtain factual information about the current state of affairs of the parties to that agreement. Rather, investors and the public should look to other disclosures contained in the Company’s filings with the U.S. Securities and Exchange Commission.

 

In addition, in connection with the Offering, the Company has agreed to pay to certain consultants and finders in Israel an aggregate fee of $410,000.

 

The securities to be issued in the Offering are exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”) pursuant to Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D promulgated thereunder. The securities have not been registered under the Securities Act and may not be resold in the United States absent registration or an exemption from registration. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

The forgoing description of the Series B Certificate of Designation, Series B-1 Certificate of Designation, Series B-2 Certificate of Designation and the Series B-3 Certificate of Designation are qualified in their entirety by reference to the full text of such document, copies of which are filed as Exhibits 3.1, 3.2, 3.3 and 3.4 to this Current Report on Form 8-K, respectively. The forgoing description of the Series B Purchase Agreement and Series B-3 Purchase Agreement are qualified by reference to the full text of these documents, copies of which are filed as Exhibit 10.1 and Exhibit 10.2, respectively, to this Current Report on Form 8-K.

 

Avenue Venture Loan and Security Agreement

 

On May 1, 2023, the Company entered into a Loan and Security Agreement, and Supplement thereto (the “LSA”), by and between the Company and its subsidiary, PsyInnovations Inc. (“PsyInnovations”), collectively as the borrowers (the “Borrowers”) and Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund, L.P., collectively as the lenders (the “Lenders”). The LSA provides for a four-year secured credit facility in an aggregate principal amount of up to $40 million (the “Loan Facility”), of which $30 million was made available on the closing date (the “Initial Tranche”) and up to $10 million (the “Discretionary Tranche”) may be made available on the later of July 1, 2023 or the date the Lender approves the issuance of the Discretionary Tranche. On May 1, 2023, the Borrowers closed on the Initial Tranche, less certain fees and expenses payable to or on behalf of the Lenders.

 

All obligations under the LSA are guaranteed by the Company’s wholly owned subsidiary, Labstyle Innovation Ltd. All obligations under the LSA, and the guarantees of those obligations, are secured by substantially all of the Company's, PsyInnovations’ and the guarantor's assets. Subject to certain milestones set forth in the LSA, the Borrowers shall make monthly payments to the Lenders of the interest at the then effective rate. If the Borrowers fail to meet the milestones set forth in the LSA, the Borrowers shall make monthly principal installments in advance in an amount sufficient to fully amortize the Loan. The Borrowers shall repay amounts outstanding under the Loan Facility in full immediately upon an acceleration as a result of an event of default as set forth in the LSA.

 

During the term of the Loan Facility, interest payable in cash by the Borrowers shall accrue on any outstanding balance due under the Loan Facility at a rate per annum equal to the higher of (x) the sum of four one-half percent (4.50%) plus the prime rate as published in the Wall Street Journal and (y) twelve and one-half percent (12.50%). During an event of default, any outstanding amount under the Loan Facility will bear interest at a rate of 5.00% in excess of the otherwise applicable rate of interest. The Borrowers will pay certain fees with respect to the Loan Facility, including an upfront commitment fee, an administration fee and a prepayment premium, as well as certain other fees and expenses of the Lenders.

 

 

The LSA contains customary events of default, including with respect to nonpayment of principal, interest, fees or other amounts; material inaccuracy of a representation or warranty; failure to perform or observe covenants; bankruptcy and insolvency events; material monetary judgment defaults; impairment of any material definitive loan documentation; other material adverse effects; key person events and change of control.

 

The LSA also contains a number of customary representations, warranties and covenants that, among other things, will limit or restrict the ability of the Company and its subsidiaries to (subject to certain qualifications and exceptions): create liens and encumbrances; incur additional indebtedness; merge, dissolve, liquidate or consolidate; make acquisitions, investments, advances or loans; dispose of or transfer assets; pay dividends or make other payments in respect of their capital stock; amend certain material documents; redeem or repurchase certain debt; engage in certain transactions with affiliates; and enter into certain restrictive agreements. In addition, the Borrowers will be required to maintain at least $5 million of unrestricted cash and cash equivalents at all times.

 

On the closing date, and with respect to the Initial Tranche only, the Company agreed to issue to the Lenders warrants (the “Warrants”) to purchase up to an aggregate of 584,884 shares of the Company’s common stock, at an exercise price of $3.334 per share, which shall have a term of five years from the issuance date. The Warrants contain customary share adjustment provisions, as well as adjustments to the number of shares issuable upon exercise of the Warrants and the exercise price in the event of a bona fide equity raise prior to September 30, 2023 at a price less than the then current exercise price. If, at any time while the Warrants are outstanding, the Company proposes to file a new registration statement for purposes of effecting an underwritten offering of its equity securities, the Lenders will be entitled to piggyback registration rights, and the Company shall afford the Lenders an opportunity to include the shares of Common Stock underlying the Warrants in that registration statement.

 

The Lenders have the right, at any time while the Loan Facility is outstanding, to convert an amount of up to $2,000,000 of the principal amount of the outstanding Loan Facility into Borrower’s unrestricted shares of the Company’s Common Stock at a price per share equal to 120% of the then effective exercise price of the Warrant.

 

As a result of the execution of the LSA and the funding of the Initial Tranche, the Company satisfied its prior Credit Agreement it previously executed with OrbiMed Royalty and Credit Opportunities III, LP (“Orbimed”), on June 9, 2022 and terminated the Credit Agreement with Orbimed.

 

The foregoing description of the terms of the LSA and the Warrant are not intended to be complete and are qualified in their entirety by reference to the LSA and the Warrant, copies of which are attached hereto as Exhibit 10.2 and 4.1, respectively, and incorporated herein by reference.

 

Preferred Agreement

 

On May 1, 2023, the Company executed an agreement (the “Preferred Agreement”) with existing holders of the Company’s Series A-1 Convertible Preferred Stock. Pursuant to the Preferred Agreement, the Company agreed to issue such holders of Series A-1 Convertible Preferred Stock up to an aggregate of an additional 382,050 shares of Common Stock, in addition to the 1,273,499 shares of common stock issuable upon conversion of the Series A-1 Preferred Stock, in consideration for such holders agreeing not to convert their shares of Series A-1 Convertible Preferred Stock. Such shares of Common Stock are issuable on the following dates, assuming the Series A-1 Convertible Preferred Stock has not yet been converted: (i) up to an aggregate of 63,675 shares of Common Stock before July 1, 2023, if not converted for at least one quarter, (ii) up to an aggregate of 127,350 shares of Common Stock before October 1, 2023, if not converted for at least two quarters, (iii) up to an aggregate of 191,026 shares of Common Stock before January 1, 2024, if not converted for at least three quarters, (iv) up to an aggregate of 254,700 shares of Common Stock before April 1, 2024, if not converted for at least four quarters, and (v) up to an aggregate of 382,050 shares of Common Stock before July 1, 2024, if not converted for at least five quarters. The holders of Series A-1 Convertible Preferred Stock will not be entitled to receive any such shares if the issuance of such shares will exceed a non-waivable 19.99% ownership blocker.

 

 

The foregoing description of the terms of the Preferred Agreement is not intended to be complete and is qualified in its entirety by reference to the Preferred Agreement, a copy of which is attached hereto as Exhibit 10.3 and incorporated herein by reference.

 

Item 1.02 Termination of a Material Defi nitive Agreement.

 

The information set forth in Item 1.01, as it relates to the Orbimed Credit Agreement, is incorporated by reference into this Item 1.02.

 

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

The information set forth in Item 1.01 is incorporated by reference into this Item 2.03.

 

Item 3.02 Unregistered Sales of Equity Securities

 

The information set forth in Item 1.01 is incorporated by reference into this Item 3.02.

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

The Certificate of Incorporation of the Company authorizes the issuance of up to 5,000,000 shares of preferred stock and further authorizes the Board of the Company to fix and determine the designation, preferences, conversion rights, or other rights, including voting rights, qualifications, limitations, or restrictions of the preferred stock.

 

On May 1, 2023, the Company filed the Series B Certificate of Designation, designating 30,000 shares of Series B Preferred Stock, the Series B-1 Certificate of Designation, designating 15,000 shares of Series B-1 Preferred Stock, and the Series B-2 Certificate of Designation, designating 15,000 shares of Series B-2 Preferred Stock in connection with the Offering.

 

On May 5, 2023, the Company filed the Series B-3 Certificate of Designation, designating 15,000 shares of Series B-3 Preferred Stock in connection with the Offering.

 

Item 8.01 Other Events.

 

On May 2, 2023, the Company issued a press release announcing the initial closing of the Offering and borrowing under the LSA. A copy of the press release is attached hereto as Exhibit 99.1.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

3.1   Certificate of Designation of Preferences, Rights and Limitations of Series B Preferred Stock (incorporated by reference to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2023).
3.2   Certificate of Designation of Preferences, Rights and Limitations of Series B-1 Preferred Stock (incorporated by reference to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2023).
3.3   Certificate of Designation of Preferences, Rights and Limitations of Series B-2 Preferred Stock (incorporated by reference to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2023).
3.4   Certificate of Designation of Preferences, Rights and Limitations of Series B-3 Preferred Stock (incorporated by reference to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2023).
4.1   Form of Warrant (incorporated by reference to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2023).
10.1   Form of Securities Purchase Agreement for Series B, Series B-1, and Series B-2 Preferred Stock(incorporated by reference to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2023).
10.2   Loan and Security Agreement, dated May 1, 2023, by and among the Company, as borrower, and Avenue Venture Opportunities Fund II, L.P., as lender (incorporated by reference to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2023).
10.3   Form of Preferred Agreement with Series A-1 Convertible Preferred Stockholders (incorporated by reference to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2023).
10.4   Form of Securities Purchase Agreement for Series B-3 Preferred Stock (incorporated by reference to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2023).
99.1   Press release of DarioHealth Corp. dated May 2, 2023 (incorporated by reference to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2023).
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: May 9, 2023 DARIOHEALTH CORP.
   
   
  By: /s/ Zvi Ben David
    Name: Zvi Ben David
    Title: Chief Financial Officer, Treasurer and Secretary

 

 EX-101.SCH 2 drio-20230501.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 drio-20230501_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 drio-20230501_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
May 01, 2023
Cover [Abstract]  
Document Type 8-K/A
Amendment Flag true
Amendment Description On May 5, 2023, DarioHealth Corp. (the "Company") filed a Current Report on Form 8-K in connection with the closing of a private placement offering and the execution of a loan and security agreement (the "Prior 8-K"). This Current Report on Form 8-K/A (the "8-K/A") is being filed to clarify the reduced number of warrant shares to be issued to the lender as well as clarify the reduced number of shares potentially issuable to holders of the Company's Series A-1 Preferred Stock. No other changes were made to the Prior 8-K and this Form 8-K/A should be read in connection with the Prior 8-K. Accordingly, except as specifically noted above, this Form 8-K/A does not reflect events occurring after the filing of the Prior 8-K. Unless filed herewith, references to the exhibits in this Form 8-K/A are references to the exhibits filed with the Prior 8-K.
Document Period End Date May 01, 2023
Current Fiscal Year End Date --12-31
Entity File Number 001-37704
Entity Registrant Name DARIOHEALTH CORP.
Entity Central Index Key 0001533998
Entity Tax Identification Number 45-2973162
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 18 W. 18th St
Entity Address, Address Line Two 5th Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10011
City Area Code 972
Local Phone Number 4-770-4055
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol DRIO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 6 tm2315045d1_8ka_htm.xml IDEA: XBRL DOCUMENT 0001533998 2023-05-01 2023-05-01 iso4217:USD shares iso4217:USD shares 0001533998 true --12-31 On May 5, 2023, DarioHealth Corp. (the "Company") filed a Current Report on Form 8-K in connection with the closing of a private placement offering and the execution of a loan and security agreement (the "Prior 8-K"). This Current Report on Form 8-K/A (the "8-K/A") is being filed to clarify the reduced number of warrant shares to be issued to the lender as well as clarify the reduced number of shares potentially issuable to holders of the Company's Series A-1 Preferred Stock. No other changes were made to the Prior 8-K and this Form 8-K/A should be read in connection with the Prior 8-K. Accordingly, except as specifically noted above, this Form 8-K/A does not reflect events occurring after the filing of the Prior 8-K. Unless filed herewith, references to the exhibits in this Form 8-K/A are references to the exhibits filed with the Prior 8-K. 8-K/A 2023-05-01 DARIOHEALTH CORP. DE 001-37704 45-2973162 18 W. 18th St 5th Floor New York NY 10011 972 4-770-4055 false false false false Common Stock, par value $0.0001 per share DRIO NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 25 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://mydario.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2315045d1_8ka.htm drio-20230501.xsd drio-20230501_lab.xml drio-20230501_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2315045d1_8ka.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 25 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2315045d1_8ka.htm" ] }, "labelLink": { "local": [ "drio-20230501_lab.xml" ] }, "presentationLink": { "local": [ "drio-20230501_pre.xml" ] }, "schema": { "local": [ "drio-20230501.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 25, "memberCustom": 0, "memberStandard": 0, "nsprefix": "drio", "nsuri": "http://mydario.com/20230501", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2315045d1_8ka.htm", "contextRef": "From2023-05-01to2023-05-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://mydario.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2315045d1_8ka.htm", "contextRef": "From2023-05-01to2023-05-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://mydario.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 13 0001104659-23-057486-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-057486-xbrl.zip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end